Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D. Moreau M, et al. Among authors: alouani e. Eur J Cancer. 2024 May;202:114033. doi: 10.1016/j.ejca.2024.114033. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38537314 Free article. Clinical Trial.
Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma.
Raufi AG, Pellicciotta I, Palermo CF, Sastra SA, Chen A, Alouani E, Maurer HC, May M, Iuga A, Rabadan R, Olive KP, Manji GA. Raufi AG, et al. Among authors: alouani e. bioRxiv [Preprint]. 2023 Dec 25:2023.12.24.573257. doi: 10.1101/2023.12.24.573257. bioRxiv. 2023. PMID: 38234792 Free PMC article. Preprint.
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C, Auclin E, Alouani E, Mercier M, Hollebecque A, Turpin A, Mazard T, Pernot S, Dutherage M, Cohen R, Borg C, Hautefeuille V, Sclafani F, Ben-Abdelghani M, Aparicio T, De La Fouchardière C, Herve C, Perkins G, Heinrich K, Kunzmann V, Gallois C, Guimbaud R, Tougeron D, Taieb J. Flecchia C, et al. Among authors: alouani e. Br J Cancer. 2024 Feb;130(3):442-449. doi: 10.1038/s41416-023-02524-3. Epub 2023 Dec 15. Br J Cancer. 2024. PMID: 38102227
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, Sonbol MB, Ticku J, Jin Z, Taieb J, Sinicrope FA. Saberzadeh-Ardestani B, et al. Among authors: alouani e. Eur J Cancer. 2024 Jan;196:113433. doi: 10.1016/j.ejca.2023.113433. Epub 2023 Nov 10. Eur J Cancer. 2024. PMID: 37979306
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E, Laparra A, Perret A, Sakkal M, Messayke S, Danlos FX, Ouali K, Hollebecque A, Even C, Ammari S, Baldini C, Champiat S, Besse B, Robert C, Guettier C, Samuel D, Lambotte O, De Martin E, Michot JM. Alouani E, et al. Eur J Cancer. 2023 Nov;193:113313. doi: 10.1016/j.ejca.2023.113313. Epub 2023 Aug 26. Eur J Cancer. 2023. PMID: 37748398
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, Dumont F, Guimbaud R, Alouani E, Passot G, Desolneux G, Ghiringhelli F, Marchal F, Mourthadhoi F, Coriat R, Desgrippes R, Locher C, Goujon G, Des Guetz G, Aparicio T, Paubelle E, Dupré A, de la Fouchardière C. Marolleau P, et al. Among authors: alouani e. Int J Cancer. 2023 Oct 1;153(7):1376-1385. doi: 10.1002/ijc.34636. Epub 2023 Jul 5. Int J Cancer. 2023. PMID: 37403609
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
Alouani E, Mercier M, Flecchia C, Auclin E, Hollebecque A, Mazard T, Turpin A, Pernot S, Cohen R, Dutherage M, Kim S, Sclafani F, Ben-Abdelghani M, Herve C, Aparicio T, De La Fouchardière C, Perkins G, Hautefeuille V, Jaffrelot M, Gallois C, Bongard V, Tougeron D, Taïeb J, Guimbaud R. Alouani E, et al. ESMO Open. 2023 Jun;8(3):101574. doi: 10.1016/j.esmoop.2023.101574. Epub 2023 May 25. ESMO Open. 2023. PMID: 37244250 Free PMC article.
Profile and outcome of cancer patients enrolled in contemporary phase I trials.
Alouani E, Gazzah A, Mercier S, Bahleda R, Hollebecque A, Michot JM, Baldini C, Ammari S, Champiat S, Marabelle A, Postel-Vinay S, Ribrag V, Loriot Y, Aix SP, Mahjoubi L. Alouani E, et al. Eur J Cancer. 2023 Jul;188:1-7. doi: 10.1016/j.ejca.2023.04.006. Epub 2023 Apr 20. Eur J Cancer. 2023. PMID: 37178645 Clinical Trial.
16 results